Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine

Psychopharmacology

Volumn 231, Issue 7, 2014, Pages 1389-1395

  Ramos Quiroga, Josep Antoni ^a,b,c   Corominas Roso, Margarida ^a   Palomar, Gloria ^a   Gomez Barros, Nuria ^a,b   Ribases, Marta ^a,b,d   Sanchez Mora, Cristina ^a,b,d   Bosch, Rosa ^a,b   Nogueira, Mariana ^a   Corrales, Montserrat ^a   Valero, Sergi ^a,b   Casas, Miguel ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ADHD; Atomoxetine; BDNF; Brain derived neurotrophic factor; Neuroplasticity

Indexed keywords

ATOMOXETINE; BRAIN DERIVED NEUROTROPHIC FACTOR; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGICAL RATING SCALE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD; CLINICAL TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896487963     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3343-y     Document Type: Article

References (43)

1. Adriani W, Leo D, Greco D, Rea M, di Porzio U, Laviola G, Perrone-Capano C (2006) Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 31:1946-1956
2. Aicardi G, Argilli E, Cappello S, Santi S, Riccio M, Thoenen H, Canossa M (2004) Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 101:15788-15792
3. Bekinschtein P, Cammarota M, Medina JH (2013) BDNF and memory processing. Neuropharmacology. doi: 10.1016/j.neuropharm.2013.04.024
4. Bergman O, Westberg L, Lichtenstein P, Eriksson E, Larsson H (2011) Study on the possible association of brain-derived neurotrophic factor polymorphism with the developmental course of symptoms of attention deficit and hyperactivity. Int J Neuropsychopharmacol 14:1367-1376
5. Britton GB (2011) Cognitive and emotional behavioural changes associated with methylphenidate treatment: a review of preclinical studies. Int J Neuropsychopharmacol. doi: 10.1017/S1461145711000472
6. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
7. Chamberlain SR, Hampshire A, Müller U et al (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65:550-555
8. Chapleau CA, Larimore JL, Theibert A, Pozzo-Miller L (2009) Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J Neurodev Disord 1:185-196
9. Conners J, Erhardt D, Sparrow E (1999) Conners' Adult ADHD Diagnostic Interview for DSM-IV. Multi-Health Systems, Nord Tonawanda, NY
10. Contini V, Rovaris DL, Victor MM, Grevet EH, Rohde LA, Bau CH (2012) Pharmacogenetics of response to methylphenidate in adult patients with attention-deficit/hyperactivity disorder (ADHD): a systematic review. Eur Neuropsychopharmacol 23:555-560
11. Corominas M, Roncero C, Ribases M, Castells X, Casas M (2007) Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology 55:2-13
12. Corominas-Roso M, Ramos-Quiroga JA, Ribases M et al (2013) Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. doi: 10.1017/S1461145712001629
13. Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, Castellanos FX (2012) Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry 169:1038-1055
14. Del'guidice T, Lemasson M, Etiévant A, Manta S, Magno LA, Escoffier G, Roman FS, Beaulieu JM (2013) Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl). doi: 10.1007/s00213-013-3212-8
15. Dillo W, Göke A, Prox-Vagedes V, Szycik GR, Roy M, Donnerstag F, Emrich HM, Ohlmeier MD (2010) Neuronal correlates of ADHD in adults with evidence for compensation strategies - a functional MRI study with a Go/No-Go paradigm. Ger Med Sci. doi: 10.3205/000098
16. Dincheva I, Glatt CE, Lee FS (2012) Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics. Neuroscientist 18:439-451
17. Fumagalli F, Racagni G, Colombo E, Riva MA (2003) BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry 8:898-899
18. Fumagalli F, Cattaneo A, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA (2010) Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 62:523-529
19. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 23:742-747
20. Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261-264
21. Kent L, Green E, Hawi Z et al (2005) Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry 10:939-943
22. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S (2011) Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 14:347-353
23. Koneski JAS, Casella EB, Agertt F, Ferreira MG (2011) Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. Epilepsy Behav 21:228-232
24. Kuntsi J, Klein C (2012) Intraindividual variability in ADHD and its implications for research of causal links. Curr Top Behav Neurosci 9:67-91
25. Lang UE, Hellweg R, Sander T, Gallinat J (2009) The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 14:120-122
26. Lanktree M, Squassina A, Krinsky M, Strauss J, Jain U, Macciardi F, Kennedy JL, Muglia P (2008) Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:945-951
27. Lee TH, Lee CH, Kim IH, Yan BC, Park JH, Kwon SH, Park OK, Ahn JH, Cho JH, Won MH, Kim SK (2012) Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus. Neurosci Lett 524:84-88
28. Lüscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69:650-663
29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83
30. Molendijk ML, Haffmans JPM, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, Elzinga BM (2012) Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS ONE 7:e48046
31. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37:1553-1561
32. Ramos-Quiroga JA, Bosch R, Richarte V et al (2012) Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. Rev Psiquiatr Salud Ment 5:229-235
33. Sánchez-Mora C, Ribasés M, Ramos-Quiroga JA et al (2010) Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet 153B:512-523
34. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P (2009) Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 42:270-276
35. Schulz KP, Fan J, Bédard A-CV, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH (2012) Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 69:952-961
36. Shim S-H, Hwangbo Y, Kwon Y-J, Jeong HY, Lee BH, Lee HJ, Kim YK (2008) Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 32:1824-1828
37. Sonuga-Barke EJS, Castellanos FX (2007) Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. Neurosci Biobehav Rev 31:977-986
38. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
39. Sun H, Cocker PJ, Zeeb FD, Winstanley CA (2012) Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex. Psychopharmacology (Berl) 219:285-301
40. Suskauer SJ, Simmonds DJ, Caffo BS, Denckla MB, Pekar JJ, Mostofsky SH (2008) fMRI of intrasubject variability in ADHD: anomalous premotor activity with prefrontal compensation. J Am Acad Child Adolesc Psychiatry 47:1141-1150
41. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50:755-760
42. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:647-655
43. Wietecha L, Young J, Ruff D, Dunn D, Findling RL, Saylor K (2012) Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD): impact of treatment on family functioning. Clin Neuropharmacol 35:125-133